BD Gets FDA Emergency Use Authorization for COVID, Influenza, RSV Combination Test
BD received Emergency Use Authorization from the US FDA for a new molecular diagnostic combination test for respiratory viruses.
Read MorePosted by Andy Lundin | Feb 8, 2023 | Flu & Respiratory Infections |
BD received Emergency Use Authorization from the US FDA for a new molecular diagnostic combination test for respiratory viruses.
Read MorePosted by Andy Lundin | Feb 6, 2023 | Leukemia |
Identifying recurrent genetic alterations in myeloid neoplasms has improved diagnosis and expanded targeted treatments available to patients.
Read MorePosted by Andy Lundin | Feb 6, 2023 | Diagnostic Technologies, Disease States |
A new saliva-based test that can predict the risk of developing different kinds of cancers and other serious diseases is now available.
Read MorePosted by Andy Lundin | Feb 3, 2023 | Covid 19 |
Immunexpress detailed a study that validated the use of its SeptiCyte RAPID as a triaging tool for COVID patients requiring hospitalization.
Read MorePosted by Andy Lundin | Feb 1, 2023 | Cancer |
Next-generation cancer strategies rely on next-generation gene sequencing (NGS), which paves the way for new tools to detect mutations.
Read More